MedElevator Войти в исследования
← Поиск публикаций

DOI 10.14309/ajg.0000000000001691

Медицинская библиотека · The American journal of gastroenterology · 2022

Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase.

Tseng Tai-Chung, Hosaka Tetsuya, Liu Chun-Jen, Suzuki Fumitaka, Hong Chun-Ming, Kumada Hiromitsu, Yang Wan-Ting, Hsu Chen-Yang, Su Tung-Hung, Yang Hung-Chih, Liu Chen-Hua, Chen Pei-Jer, Chen Hsiu-Hsi, Kao Jia-Horng

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

INTRODUCTION

Many patients with chronic hepatitis B (CHB) are classified as indeterminate patients because they fall outside the defined CHB phases. We aimed to explore hepatocellular carcinoma (HCC) risk in hepatitis B e antigen (HBeAg)-negative patients with indeterminate phase and investigated whether the risk could be stratified by serum levels of hepatitis B core-related antigen (HBcrAg).

METHODS

Two retrospective cohorts enrolling HBeAg-negative, treatment-naïve CHB patients without cirrhosis were constructed (N = 2,150 in Taiwanese discovery cohort and N = 1,312 in Japanese validation cohort with a mean follow-up period of 15.88 and 12.07 years, respectively). The primary end point was HCC development.

RESULTS

According to the American Association for the Study of Liver Disease guidelines, 990 (46%) HBeAg-negative patients had indeterminate CHB phase at baseline in the Taiwanese cohort. Compared with the patients with inactive CHB and those with immune-active CHB, the indeterminate patients exhibited intermediate but diverse risk of HCC. When HCC risk was stratified by a HBcrAg level of 10,000 U/mL, 10-year HCC cumulative incidence was 0.51% and 5.33% for low HBcrAg and high HBcrAg groups, respectively, with a hazard ratio of 4.47 (95% confidence interval: 2.62-7.63). This cutoff was validated to stratify HCC risk not only in different subgroup analyses but also in an independent Japanese cohort. Finally, the overall HBeAg-negative CHB patients could be simply reclassified into high-risk and low-risk groups by combining ALT, hepatitis B virus DNA, and HBcrAg levels in both cohorts.

DISCUSSION: Serum HBcrAg level of 10,000 U/mL stratifies HCC risk in HBeAg-negative patients with indeterminate phase, which is useful for optimizing their clinical management.

Для цитирования: Tseng Tai-Chung, Hosaka Tetsuya, Liu Chun-Jen, Suzuki Fumitaka, Hong Chun-Ming, Kumada Hiromitsu, Yang Wan-Ting, Hsu Chen-Yang, Su Tung-Hung, Yang Hung-Chih, Liu Chen-Hua, Chen Pei-Jer, Chen Hsiu-Hsi, Kao Jia-Horng. Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase.. The American journal of gastroenterology. 2022. DOI: 10.14309/ajg.0000000000001691.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.